Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease

[1]  D. Atar,et al.  Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis , 2021, Clinical Research in Cardiology.

[2]  Sheyu Li,et al.  Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis , 2021, Frontiers in Endocrinology.

[3]  G. Santulli,et al.  SGLT2 Inhibitors in Cardiovascular Medicine. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[4]  Ze-Lin Zhan,et al.  Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2021, Frontiers in Endocrinology.

[5]  David W. Johnson,et al.  Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials , 2021, BMJ.

[6]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[7]  R. Chien,et al.  SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews , 2020, BMJ Open Diabetes Research & Care.

[8]  A. Levin,et al.  Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. , 2020, The lancet. Diabetes & endocrinology.

[9]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[10]  B. Merkely,et al.  Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure , 2020, Cardiovascular Diabetology.

[11]  L. Lix,et al.  Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study , 2020, BMJ.

[12]  K. Node,et al.  Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study , 2020, Endocrinology, diabetes & metabolism.

[13]  A. Banerjee,et al.  Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , 2020, Diabetes, obesity & metabolism.

[14]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[15]  J. Shaw,et al.  Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[16]  D. Matthews,et al.  Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes , 2020, Annals of Internal Medicine.

[17]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[18]  W. Chung,et al.  Demographics and medical disorders associated with smoking: a population-based study , 2020, BMC Public Health.

[19]  Y. Kao Yang,et al.  Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients , 2020, Cardiovascular Diabetology.

[20]  Y. Kao Yang,et al.  Effects of sodium‐glucose co‐transporter‐2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi‐institutional cohort study , 2020, Diabetes, obesity & metabolism.

[21]  Szu-Tah Chen,et al.  Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages , 2019, Front. Endocrinol..

[22]  M. Scharf,et al.  Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12‐week randomized controlled trial , 2019, Diabetes, obesity & metabolism.

[23]  K. Kinugawa,et al.  Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus , 2019, Circulation reports.

[24]  E. Lai,et al.  Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study , 2019, Cardiovascular Diabetology.

[25]  Y. Kao Yang,et al.  The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan , 2019, Pharmacoepidemiology and drug safety.

[26]  E. Paschetta,et al.  Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials , 2019, BMJ.

[27]  A. Figueiras,et al.  Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review , 2019, BMC Medical Research Methodology.

[28]  J. Mukai,et al.  Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus , 2019, Cardiovascular Diabetology.

[29]  Tyler J. VanderWeele,et al.  Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies , 2019, JAMA.

[30]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[31]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[32]  M. Kulldorff,et al.  Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. , 2018, Circulation.

[33]  S. Anker,et al.  Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle , 2018, ESC heart failure.

[34]  J. Shaw,et al.  Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. , 2018, Journal of the American College of Cardiology.

[35]  Mei-Ching Lee,et al.  Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease , 2018, JAMA.

[36]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[37]  B. Carstensen,et al.  Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. , 2017, The Lancet Diabetes and Endocrinology.

[38]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[39]  T. Power,et al.  Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis , 2017, Cardiovascular Diabetology.

[40]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[41]  C. Yancy,et al.  Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association , 2017, Circulation.

[42]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[43]  L. See,et al.  Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. , 2016, Journal of the American College of Cardiology.

[44]  A. Goldfine,et al.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations , 2016, Circulation.

[45]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[46]  T. Mansfield,et al.  Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. , 2016, The lancet. Diabetes & endocrinology.

[47]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[48]  J. Haukoos,et al.  The Propensity Score. , 2015, JAMA.

[49]  J. Faillie.  Indication bias or protopathic bias? , 2015, British journal of clinical pharmacology.

[50]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[51]  Barry R. Davis,et al.  Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality , 2015, Annals of Internal Medicine.

[52]  P. Rothenberg,et al.  Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study , 2015, Diabetes, obesity and metabolism.

[53]  I. Tikkanen,et al.  Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.

[54]  C. Reid,et al.  Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients , 2014, Journal of hypertension.

[55]  Elizabeth A Stuart,et al.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[56]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[57]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[58]  V. Basevi.  Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[59]  Peter C Austin,et al.  A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.

[60]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[61]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[62]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[63]  A. Goldfine,et al.  Clinical Update : Cardiovascular Disease in Diabetes Mellitus , 2016, APIK Journal of Internal Medicine.

[64]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..